Skye Bioscience Signs $22M Equity Line with Redmile, Adds $5M Warrant
SKYE is trading near its 52-week low of $1.97 (10% above the low) on elevated volume (2.6× avg).
Summary
Skye Bioscience finalized a $22 million equity line of credit with Redmile Group, plus a $5 million warrant, providing a capital backstop for its pending Redx Pharma reverse merger while creating ongoing dilution.
Key Events · Financing and Capital Events · SKYE
-
$22M Equity Line Finalized
Definitive Equity Purchase Agreement with Redmile Biopharma Investments III, L.P. for up to $22,000,000 in share purchases over three years, with monthly draws capped at $2,000,000.
-
$5M Warrant Issued
Redmile receives a warrant to purchase $5,000,000 of shares at an exercise price equal to the lesser of PIPE Price or Market Price, with a 90% of PIPE Price floor, exercisable January 2027 through January 2030.
-
19.99% Exchange Cap
Issuance capped at 7,080,740 shares (19.99% of outstanding common stock) unless stockholder approval obtained; 9.99% beneficial ownership blocker with non-voting share alternative.
-
Registration Rights
Registration Rights Agreement requires resale registration statement filed within 10 business days of Closing Date, with effectiveness deadlines.
Analysis · SKYE · Life Sciences
On August 21, 2026, Skye Bioscience converted its previously disclosed term sheet with Redmile Group into definitive agreements. The equity line of credit (ELOC) allows Skye to sell up to $22 million of shares to Redmile over three years, with monthly draws capped at $2 million. The purchase price is the lesser of the PIPE price or market price, with a 10% discount floor to the PIPE price. Redmile also receives a warrant to purchase $5 million of shares at an exercise price tied to the PIPE price or market price, exercisable from January 2027 through January 2030. The deal is capped at 19.99% of outstanding shares (7,080,740 shares) unless stockholders approve more. This financing provides a committed capital backstop for the pending Redx Pharma reverse merger, but the ELOC structure means Skye will be issuing shares into the market monthly, creating ongoing dilution pressure. The 9.99% beneficial ownership blocker and non-voting share alternative are standard protections. Against the backdrop of Skye's Nasdaq delisting notice and going-concern warning if the Redx deal fails, this ELOC is a survival mechanism — but one that comes with meaningful dilution risk for existing holders.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 29.4% of the 2796 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SKYE was trading at $2.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.3M. The 52-week trading range was $1.97 to $39.92. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.